Genmab Announces Phase II Study of Daratumumab in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma

Company Announcement

  • First study of daratumumab in smoldering multiple myeloma
  • Study expected to start in  2015

Copenhagen, Denmark; November 24, 2014 – Genmab A/S (OMX: GEN) announced today that its collaboration partner, Janssen Biotech, Inc. (Janssen) plans to start a Phase II study of daratumumab in smoldering multiple myeloma.  The study (SMM2001) will evaluate three different dose schedules of daratumumab for the treatment of smoldering multiple myeloma.  The study is expected to start enrolling patients in 2015.

“We are pleased to announce this study, which illustrates that the development plan for daratumumab encompasses all stages of multiple myeloma. Smoldering multiple myeloma is a challenging indication, as physicians will evaluate treating patients at an early stage of the disease, with the intent to extend the period before the disease transitions to symptomatic multiple myeloma,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About the SMM2001 study
This Phase II study will be a randomized, open-label, multicenter study and will enroll approximately 120 patients with high risk smoldering multiple myeloma.  Patients will be randomized to receive one of three dose schedules of daratumumab.  The study will be conducted by Janssen Research & Development LLC.

About daratumumab
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab may also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma.  Daratumumab has been granted Breakthrough Therapy Designation from the US FDA  for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD.  In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in late stage clinical development for multiple myeloma. Additionally Genmab has a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody™ and UniBody ® . Arzerra ® is a registered trademark of the GSK group of companies.

Company Announcement no. 56
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 104

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Cold Stone’s Holiday Menu Is a Franchisee Traffic Test

Updated Category News Views 56

Peppermint, caramel, and red velvet arrive right when dessert budgets loosen up. Cold Stone Creamery has rolled out a holiday menu running through January 5, 2027, and this is the sort of modest, practical promotion that matters more to a franchise system than the glittery language around it. Nobody should confuse two seasonal ice cream flavors with a corporate...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 104

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
California's AI Oversight Roadmap Raises the Bar Early

Updated Category News Views 41

California has put a real set of teeth on the table, at least on paper. Governor Gavin Newsom's November 18 roadmap for implementing the state's new AI laws embraces an independent verification organization, or IVO, framework that Fathom has been pushing: outside evaluators, licensed by the state, examining whether frontier AI systems create catastrophic risks. For anyone...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 58

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 66

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 0

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 139

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 229

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US to Showcase Innovations at Capital Markets Day

Updated Category News Views 104

T-Mobile US, Inc. Unveils Plans at Deutsche Telekom Capital Markets Day BELLEVUE, Wash. — T-Mobile US, Inc. (NASDAQ: TMUS) is gearing up to present at the highly anticipated Deutsche Telekom Capital Markets Day, a pivotal event that showcases the company's strategic vision and operational milestones. The presentation will feature insights from Mike Sievert, T-Mobile’s...

Continue Reading
Earnings Insights for Edwards Lifesciences: What to Expect

Updated Category News Views 84

Understanding Edwards Lifesciences's Expected Earnings Release Edwards Lifesciences (NYSE: EW) is gearing up to announce its quarterly earnings, creating a buzz among investors eager for insights on the company's performance. With analysts forecasting an earnings per share (EPS) of $0.65, stakeholders are looking forward to how these results may impact the stock price and...

Continue Reading
Understanding ezPaycheck: A Smart Solution for Restaurant Payroll

Updated Category News Views 139

Introducing ezPaycheck: Tailored Payroll Solution for Restaurants ezPaycheck is designed for restaurant owners who prioritize precision and efficiency in managing payroll. This cutting-edge software allows users to streamline their payroll processes, offering a risk-free trial for up to 30 days to evaluate compatibility with existing systems. Why Choose ezPaycheck for...

Continue Reading
Revolutionizing Pet Compliance with AI: PetScreening Unveils Tool

Updated Category News Views 638

PetScreening Introduces Innovative AI Compliance Tool The solution will help operators capture pet-related revenue that otherwise would have been lost. PetComply.ai Launch Today, PetScreening, a leader in pet policy compliance software, has launched PetComply.ai, an exclusive feature designed to assist property managers in identifying undisclosed pets by renters. This...

Continue Reading
STRATA Skin Sciences Announces Participation in Investor Conference

Updated Category News Views 99

STRATA Skin Sciences Joins the Benchmark Company Investor Conference STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a pioneering medical technology company focused on innovative solutions for dermatologic conditions, has announced participation in the upcoming Benchmark Company 13th Annual Discovery Investor Conference. This event will take place at the New York Athletic...

Continue Reading